Chemotherapy-Induced Fatigue Correlates With Higher Fatigue Scores Before Treatment.

PURPOSE: Cancer chemotherapy can induce fatigue in about 20% to 30% of patients. So far, there is very little information as to the predictors of chemotherapy-induced fatigue (CIF). We evaluated potential predictors of CIF in a sample of patients with cancer with several types of solid tumors scheduled to receive chemotherapy according to institutional protocols. METHODS: Before their first and second chemotherapy cycles, patients answered to the Brief Fatigue Inventory (BFI), Chalder, Mini Nutritional Assessment (MNA), Stress thermometer, and HADS questionnaires as well as provided blood samples for inflammatory markers. RESULTS: We evaluated 52 patients, 37 (71%) were female and mean age was 53 years. The most common tumors were breast cancer 21 (40%) and gastrointestinal tumors 12 (23%). Although 14 (25.2%) patients had an increase in their fatigue BFI scores equal or above 3 points from baseline, we observed no significant overall differences between BFI scores before and after chemotherapy. The only 2 factors associated with an increase of 3 points in the BFI scores after chemotherapy were race and higher baseline BFI levels. By multivariate analysis, overall BFI and Chalder scores after chemotherapy also correlated significantly with their respective baseline scores before treatment. HADS scores before treatment correlated with overall BFI scores postchemotherapy, whereas MNA scores before chemotherapy and female sex correlated with higher Chalder scores after treatment. CONCLUSION: We conclude that fatigue induced by chemotherapy is common and consistently associated with higher fatigue scores before treatment. Screening for fatigue before chemotherapy may help to identify patients who are prone to develop CIF.

Prevalência do câncer em dois serviços públicos atendidos pela Disciplina de Oncologia e Hematologia da Faculdade de Medicina da Fundação ABC (FMABC) / Cancer prevalence in two public services coordinated by the Department of Oncology and Hematology, ABC Foundation School of Medicine (FMABC)

Objetivos: Analisar as características dos pacientes que frequentam os serviços de Oncologia da FMABC e comparar com as estatísticas acionais e da região. Métodos: Trata-se de um levantamento epidemiológico conduzido de 14/9/2010 a 18/5/2011 nos ambulatórios de oncologia de dois hospitais públicos da região do grande ABC, que tabulou de forma sistemática as características clínicas dos pacientes atendidos. Resultados: Do total de 2.366 pacientes avaliados, 60% eram oriundos do Hospital Mário Covas, 63% eram mulheres, com idade média de 60,25 (12-105) anos. Os tumores mais prevalentes foram: mama (31,6%), colorretal (14,8%), próstata (11,2%), linfoma não Hodgkin (6%) e estômago (3,9%). Do total de pacientes (excetuando-se linfoma não Hodgkin), 15,3% apresentaram metástase no momento da sua inclusão. Conclusões: Em comparação com os dados do INCA para o Brasil e região Sudeste de 2010, nosso serviço apresenta significativamente mais casos de câncer de mama (31,5% FMABC versus 13% Brasil e 13,6% Sudeste) e menor número de casos de câncer de pulmão (2,5% FMABC versus 7,36% Brasil e 6,7% Sudeste). Volumes diferentes de cirurgias oncológicas nos diversos serviços de referência de nossa instituição, assim como maior intensidade de medidas preventivas para câncer de mama podem explicar parte das diferenças observadas. Não podemos excluir, todavia, fatores epidemiológicos específicos regionais para explicar a alta prevalência de câncer de mama na região do ABC.